Logo

Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic Kidney Disease

Share this
Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic Kidney Disease

Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic Kidney Disease

Shots:

  • Evotec to receive $179M/ product as upfront- research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and commercialization of the therapies
  • The companies will share responsibilities during drug discovery and pre-clinical development and will jointly identify and develop novel targets based on medical and molecular data sets of thousands of CKD patients
  • The collaboration allows Novo Nordisk to expand its portfolio beyond diabetes targeting the unmet medical needs of patients

Click here ­to­ read full press release/ article | Ref: Novo Nordisk | Image: GMP News


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions